News & Updates

The addition of hormone therapy, either short- or long-term, to postoperative radiotherapy (PORT) offers no survival advantage over PORT alone in prostate cancer, especially for men with very low pre-PORT prostate specific antigen (PSA) levels, according to the POSEIDON study.

Adding enzalutamide to radium-223 significantly improves overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with enzalutamide alone, according to the phase III EORTC 1333/PEACE-3 trial presented at ASCO GU 2026.

Drinking coffee appears to confer survival gains and reduce the risk of recurrence in patients with colorectal cancer (CRC), according to a meta-analysis.

A genetically engineered pig liver has been successfully transplanted in a living human, according to a recent study, noting the challenge posed by postoperative xenotransplantation-associated thrombotic microangiopathy (xTMA) to long-term success.

In the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), the combination of tislelizumab plus chemotherapy confers sustained survival benefit, according to 3-year data from the RATIONALE-309 trial.

Concurrent use of a glucagon-like peptide-1 receptor agonist (GLP-1RA) and progestins appears to protect against the risk of endometrial cancer in women with benign uterine pathology or endometrial hyperplasia, according to a real-world study.